These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 10581767)

  • 1. [Antiplatelet therapy].
    Ikeda Y
    Nihon Naika Gakkai Zasshi; 1999 Sep; 88(9):1802-11. PubMed ID: 10581767
    [No Abstract]   [Full Text] [Related]  

  • 2. Antithrombotic therapy in cardiac stent patients.
    Cannan CR
    Curr Cardiol Rep; 2001 Jan; 3(1):78-84. PubMed ID: 11139803
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antiplatelet therapy for ischemic heart disease.
    Lange RA; Hillis LD
    N Engl J Med; 2004 Jan; 350(3):277-80. PubMed ID: 14724308
    [No Abstract]   [Full Text] [Related]  

  • 4. Evolution of improved antithrombotic and antiplatelet agents: genesis of the Comparison of Abciximab Complications with Hirulog [and back-Up Abciximab] Events Trial (CACHET).
    Topol EJ
    Am J Cardiol; 1998 Oct; 82(8B):63P-68P. PubMed ID: 9809894
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aspirin beyond platelet inhibition.
    Verheugt FW; Gersh BJ
    Am J Cardiol; 2002 Jul; 90(1):39-41. PubMed ID: 12088777
    [No Abstract]   [Full Text] [Related]  

  • 6. Effects of clopidogrel pretreatment before percutaneous coronary intervention in patients treated with glycoprotein IIb/IIIa inhibitors (abciximab or tirofiban).
    Assali AR; Salloum J; Sdringola S; Moustapha A; Ghani M; Hale S; Schroth G; Fujise K; Anderson HV; Smalling RW; Rosales OR
    Am J Cardiol; 2001 Oct; 88(8):884-6, A6. PubMed ID: 11676953
    [No Abstract]   [Full Text] [Related]  

  • 7. Optimizing antiplatelet therapy in coronary interventions.
    King SB
    Clin Cardiol; 2000 Nov; 23 Suppl 6(Suppl 6):VI-8-13. PubMed ID: 11129685
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and efficacy of abciximab as an adjunct to percutaneous coronary intervention.
    Vergara-Jimenez J; Tricoci P
    Vasc Health Risk Manag; 2010 Mar; 6():39-45. PubMed ID: 20234778
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New antiplatelet agents.
    White HD; French JK; Ellis CJ
    Aust N Z J Med; 1998 Aug; 28(4):558-64. PubMed ID: 9777140
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of platelet surface receptors and early changes in platelet function in patients with STEMI treated with abciximab and clopidogrel versus clopidogrel alone.
    Konopka A; Spychalska J; Sitkiewicz D; Zdebska E; Pilichowska I; Piotrowski W; Stepińska J
    Am J Cardiovasc Drugs; 2007; 7(6):433-9. PubMed ID: 18076210
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Does pre-treatment with aspirin and loading dose clopidogrel obviate the need for glycoprotein IIb/IIIa antagonists during elective coronary stenting? A focus on peri-procedural myonecrosis.
    Claeys MJ; Van der Planken MG; Bosmans JM; Michiels JJ; Vertessen F; Van Der Goten P; Wuyts FL; Vrints CJ
    Eur Heart J; 2005 Mar; 26(6):567-75. PubMed ID: 15618034
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Blocking platelets more: are we skating on thin ice?
    Choussat R; Montalescot G
    Heart; 1998 Jan; 79(1):5-6. PubMed ID: 9505907
    [No Abstract]   [Full Text] [Related]  

  • 13. Contemporary use of antiplatelet therapies in percutaneous coronary interventions.
    Saw J; Moliterno DJ
    Coron Artery Dis; 2003 Aug; 14(5):373-80. PubMed ID: 12878902
    [No Abstract]   [Full Text] [Related]  

  • 14. Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade.
    EPISTENT Investigators
    Lancet; 1998 Jul; 352(9122):87-92. PubMed ID: 9672272
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Platelets: is aspirin sufficient or must we know how to pronounce abciximab?
    Brinkman WT; Terramani TT; Najibi S; Chaikof EL
    Semin Vasc Surg; 2002 Dec; 15(4):245-55. PubMed ID: 12478499
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Glycoprotein IIb/IIIa inhibitors improve outcome after coronary stenting in clopidogrel nonresponders: a prospective, randomized study.
    Cuisset T; Frere C; Quilici J; Morange PE; Mouret JP; Bali L; Moro PJ; Lambert M; Alessi MC; Bonnet JL
    JACC Cardiovasc Interv; 2008 Dec; 1(6):649-53. PubMed ID: 19463379
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of turbidimetric aggregation and in vitro bleeding time (PFA-100) for monitoring the platelet inhibitory profile of antiplatelet agents in patients undergoing stent implantation.
    Van der Planken MG; Claeys MJ; Vertessen FJ; Dilling D; Bosmans JM; Berneman ZN; Michiels JJ; Vrints C
    Thromb Res; 2003; 111(3):159-64. PubMed ID: 14678814
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antithrombotic therapy in the cardiac catheterization laboratory: focus on antiplatelet agents.
    Furman MI; Frelinger III AL; Michelson AD
    Curr Cardiol Rep; 2000 Sep; 2(5):386-94. PubMed ID: 10980905
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Appropriate antiplatelet and antithrombotic therapy in patients with acute coronary syndromes: recent updates to the ACC/AHA guidelines.
    Mehta SR;
    J Invasive Cardiol; 2002 Dec; 14 Suppl E():27E-34E; quiz 35E. PubMed ID: 12668860
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clopidogrel treatment prior to percutaneous coronary intervention: when enough isn't enough.
    Steinhubl SR; Charnigo R
    JAMA; 2006 Apr; 295(13):1581-2. PubMed ID: 16533936
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.